Jaeger Deborah, Marquez Alexandra M, Kosmopoulos Marinos, Gutierrez Alejandra, Gaisendrees Christopher, Orchard Devin, Chouihed Tahar, Yannopoulos Demetri
Center for Resuscitation Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
INSERM U 1116, University of Lorraine, 54500 Vandœuvre-lès-Nancy, France.
Rev Cardiovasc Med. 2023 Jun 6;24(6):163. doi: 10.31083/j.rcm2406163. eCollection 2023 Jun.
Drugs are used during cardiopulmonary resuscitation (CPR) in association with chest compressions and ventilation. The main purpose of drugs during resuscitation is either to improve coronary perfusion pressure and myocardial perfusion in order to achieve return of spontaneous circulation (ROSC). The aim of this up-to-date review is to provide an overview of the main drugs used during cardiac arrest (CA), highlighting their historical context, pharmacology, and the data to support them. Epinephrine remains the only recommended vasopressor. Regardless of the controversy about optimal dosage and interval between doses in recent papers, epinephrine should be administered as early as possible to be the most effective in non-shockable rhythms. Despite inconsistent survival outcomes, amiodarone and lidocaine are the only two recommended antiarrhythmics to treat shockable rhythms after defibrillation. Beta-blockers have also been recently evaluated as antiarrhythmic drugs and show promising results but further evaluation is needed. Calcium, sodium bicarbonate, and magnesium are still widely used during resuscitation but have shown no benefit. Available data may even suggest a harmful effect and they are no longer recommended during routine CPR. In experimental studies, sodium nitroprusside showed an increase in survival and favorable neurological outcome when combined with enhanced CPR, but as of today, no clinical data is available. Finally, we review drug administration in pediatric CA. Epinephrine is recommended in pediatric CA and, although they have not shown any improvement in survival or neurological outcome, antiarrhythmic drugs have a 2b recommendation in the current guidelines for shockable rhythms.
在心肺复苏(CPR)过程中,药物与胸外按压和通气联合使用。复苏期间使用药物的主要目的是提高冠状动脉灌注压和心肌灌注,以实现自主循环恢复(ROSC)。本最新综述的目的是概述心脏骤停(CA)期间使用的主要药物,重点介绍其历史背景、药理学以及支持它们的数据。肾上腺素仍然是唯一推荐使用的血管加压药。尽管近期论文中关于最佳剂量和给药间隔存在争议,但肾上腺素应尽早给药,以便在不可电击心律中发挥最大效果。尽管生存结果不一致,但胺碘酮和利多卡因是除颤后治疗可电击心律仅有的两种推荐抗心律失常药物。β受体阻滞剂最近也被评估为抗心律失常药物,并显示出有前景的结果,但仍需要进一步评估。钙、碳酸氢钠和镁在复苏期间仍被广泛使用,但未显示出有益效果。现有数据甚至可能表明存在有害影响,因此在常规心肺复苏期间不再推荐使用。在实验研究中,硝普钠与强化心肺复苏联合使用时,生存率有所提高,神经功能结局良好,但截至目前,尚无临床数据。最后,我们回顾了小儿心脏骤停时的药物给药情况。肾上腺素在小儿心脏骤停中被推荐使用,尽管抗心律失常药物在生存率或神经功能结局方面未显示出任何改善,但在当前指南中对于可电击心律有IIb类推荐。